Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.drudis.2020.03.019 http://scihub22266oqcxt.onion/10.1016/j.drudis.2020.03.019 32320852!7167229!32320852     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32320852.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Drug+Discov+Today 2020 ; 25 (5): 928-941 Nephropedia Template TP {{tp|p=32320852|t=2020. Deja vu: Stimulating open drug discovery for SARS-CoV-2 |pdf=|usr=}}{{32320852}} gab.com Text Deja vu: Stimulating open drug discovery for SARS-CoV-2 JO: Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=32320852 #FOAvip In the past decade we have seen two major Ebola virus outbreaks in Africa, the Zika virus in Brazil and the Americas and the current pandemic of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There is a strong sense of deja vu because there are still no effective treatments. In the COVID-19 pandemic, despite being a new virus, there are already drugs suggested as active in in vitro assays that are being repurposed in clinical trials. Promising SARS-CoV-2 viral targets and computational approaches are described and discussed. Here, we propose, based on open antiviral drug discovery approaches for previous outbreaks, that there could still be gaps in our approach to drug discovery. Twit Text FOAVip Deja vu: Stimulating open drug discovery for SARS-CoV-2 ????Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=32320852 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32320852 #FOAvip English Wikipedia <ref>{{Cite pmid|32320852}}</ref> Deja vu: Stimulating open drug discovery for SARS-CoV-2 #MMPMID32320852 Ekins S; Mottin M; Ramos PRPS; Sousa BKP; Neves BJ; Foil DH; Zorn KM; Braga RC; Coffee M; Southan C; Puhl AC; Andrade CH Drug Discov Today 2020[May]; 25 (5): 928-941 PMID32320852show ga In the past decade we have seen two major Ebola virus outbreaks in Africa, the Zika virus in Brazil and the Americas and the current pandemic of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There is a strong sense of deja vu because there are still no effective treatments. In the COVID-19 pandemic, despite being a new virus, there are already drugs suggested as active in in vitro assays that are being repurposed in clinical trials. Promising SARS-CoV-2 viral targets and computational approaches are described and discussed. Here, we propose, based on open antiviral drug discovery approaches for previous outbreaks, that there could still be gaps in our approach to drug discovery. |*Drug Discovery[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Animals[MESH] |Antiviral Agents/*pharmacology/*therapeutic use[MESH] |Betacoronavirus/*drug effects/metabolism[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Chlorocebus aethiops[MESH] |Computer Simulation[MESH] |Coronavirus Infections/*drug therapy[MESH] |Drug Repositioning[MESH] |Hemorrhagic Fever, Ebola/drug therapy[MESH] |Humans[MESH] |In Vitro Techniques[MESH] |Middle East Respiratory Syndrome Coronavirus[MESH] |Molecular Docking Simulation[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A/metabolism[MESH] |Pneumonia, Viral/*drug therapy[MESH] |SARS-CoV-2[MESH] |Severe Acute Respiratory Syndrome/drug therapy[MESH] |Severe acute respiratory syndrome-related coronavirus[MESH] |Spike Glycoprotein, Coronavirus/metabolism[MESH] |Vero Cells[MESH]Deja vu: Stimulating open drug discovery for SARS-CoV-2 (epmc).pdf DeepDyve Pubget Overpricing